GlassScriptPhysician profile
Jason Rich
NPI 1215341235
$1,835.88
in general payments reported to CMS, 2019-2025
25 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $228 · 2021: $162 · 2022: $314 · 2023: $494 · 2024: $136 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $200.68 | 2019-2025 | Dyanavel Xr |
| Pfizer INC. | $197.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $192.62 | 2019-2025 | Bexsero, Penmenvy, Menveo |
| Genentech USA, INC. | $171.08 | 2019-2021 | |
| Corium, LLC | $147.67 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $139.78 | 2019-2024 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $117.65 | 2023 | |
| Cranial Technologies, INC | $109.71 | 2019-2024 | Doc Band |
| Merck Sharp & Dohme LLC | $102.82 | 2019-2023 | Gardasil 9, Vaxelis, Rotateq |
| Sanofi Pasteur INC. | $81.39 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $42.92 | 2025 | Jornay Pm |
| Phadia US INC. | $39.59 | 2021-2024 | Immunocap |
| Astrazeneca Pharmaceuticals LP | $34.71 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $33.11 | 2019-2021 | |
| Kaleo, INC. | $32.70 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.74 | 2024-2025 | Zoryve |
| Amgen INC. | $28.71 | 2019 | |
| Biogen, INC. | $24.40 | 2023 | Spinraza |
| Teva Pharmaceuticals USA, INC. | $23.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.39 | 2020 | |
| Alk-Abello, INC | $15.73 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.19 | 2020 | |
| Novo Nordisk INC | $12.43 | 2019 | |
| Antares Pharma, INC. | $12.39 | 2019 | |
| Shire North American Group INC | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.